Eye drops could replace needle injections for wet AMD
NCT ID NCT07607561
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2a trial tests SCAI-005 eye drops in 50 adults with wet age-related macular degeneration (AMD). Participants will receive either a low dose, high dose, or placebo drops three times daily. The study aims to see if the drops can reduce retinal swelling and control the disease, potentially offering a less invasive alternative to current eye injections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SCAI-005 (axitinib) eye drops
- What this could lead to
- If successful, this could offer a less invasive eye drop alternative to regular injections for managing wet AMD.
- What could go wrong
- This is an early Phase 2a trial with only 50 participants, so results may not confirm effectiveness. The treatment is not a cure and aims only to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Longer-Lasting eye injection could cut treatment visits for macular disease
- Can a VR maze reveal hidden vision loss in macular degeneration?
- Can a new eye injection save vision in wet AMD?
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness